Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
E-VIRTUE
Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)
- NCT06041503 ↗
- Recruiting
- National Cancer Institute (NCI)
- Focused
We haven't built an HCP commentary report on E-VIRTUE (enfortumab vedotin; enfortumab vedotin plus pembrolizumab in rare genitourinary tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on E-VIRTUE so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Multicenter Study of Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Adenocarcinoma of the Bladder; Squamous Cell Carcinoma of the Bladder; Testicular Germ Cell Tumors
- Interventions
- Pembrolizumab; Enfortumab vedotin
- Arms
- Arm 1 · Experimental
- Arm 2 · Experimental
- Enrollment
- 68 (estimated)
- Primary outcomes
- Objective response rate (ORR)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Jan 20, 2026
- Primary completion
- Oct 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06041503 · updated Aug 13, 2026
Publications
linked from the registry- Chandran EBA, Atiq S, Simon N, Girardi D, Ley L, Cordes L, Patel R, Wang TF, Kydd AR, Redd B, Boudjadi S, Stukes I, Banday R, Smith E, Akbulut D, Niglio S, Gurram S, Steinberg S, Apolo AB. E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors-design and rationale. Future Oncol. 2025 Jun;21(13):1625-1630. doi: 10.1080/14796694.2025.2497719. Epub 2025 May 27. PubMed 40421891